Join the Renal Failure group to help and get support from people like you.
Renal Failure News (Page 3)
Related terms: Acute Kidney Failure, Acute Renal Failure, Chronic Renal Failure, Kidney Failure, CRF
Obese Kids Could Be at Risk for Kidney Trouble Later
FRIDAY, Jan. 5, 2024 – Teenagers who've packed on extra pounds have a significantly increased risk of developing kidney disease as a young adult, a new study finds. Obesity increased risk of later...
Frequency of Adding Salt to Foods Linked to Higher Risk for CKD
THURSDAY, Dec. 28, 2023 – A higher self-reported frequency of adding salt to foods is associated with a higher risk for chronic kidney disease (CKD) in the general population, according to a study...
Experimental Drug Could Be Big Advance Against Kidney Disease
TUESDAY, Dec. 19, 2023 – Early results from a trial of a new kidney disease medication show it significantly reduces levels of a urine marker of kidney damage. The experimental drug – called BI...
High BMI in Adolescence Linked to Early CKD in Young Adulthood
MONDAY, Dec. 11, 2023 – High body mass index (BMI) in late adolescence is associated with early chronic kidney disease (CKD) in young adulthood, according to a study published online Dec. 11 in JAMA...
Hispanics With Kidney Disease Face Higher Risk for Cardiac Arrest
THURSDAY, Oct. 12, 2023 – Hispanic folks with chronic kidney disease should have early heart health screenings, new research suggests, because they’re at high risk for sudden cardiac arrest. A team f...
Similar Management Seen for Dialysis-Requiring AKI, ESKD Patients
THURSDAY, Oct. 5, 2023 – Patients with dialysis-requiring acute kidney injury (AKI-D) are prescribed the same dialysis as end-stage kidney disease (ESKD) patients, but some AKI-D patients have the...
Your Wrist Could Give Clues to Future Health
MONDAY, Sept. 25, 2023 – One day, it may be possible to monitor people for risk of disease through continuously measuring skin temperature. Researchers have found in a new study that wrist...
Benefit of ICD Attenuated in CKD Patients Receiving Cardiac Resynchronization
MONDAY, Sept. 25, 2023 – For patients with advanced chronic kidney disease (CKD) receiving cardiac resynchronization therapy (CRT), the benefit of an implantable cardioverter defibrillator (ICD) may...
Budesonide Yields Durable Reduction in eGFR for IgA Nephropathy
MONDAY, Aug. 21, 2023 – For patients with immunoglobulin A (IgA) nephropathy, nine months of treatment with targeted-release formulation of budesonide (Nefecon) yields a greater reduction in...
Ignore That New TikTok Trend: Eating Borax Is Dangerous
THURSDAY, Aug. 17, 2023 – Despite what you see on TikTok, don’t consume the laundry powder borax to relieve pain and inflammation or boost bone health. Even though videos on the social media site t...
Promising Outcomes Seen for Living Kidney Donors With HIV
MONDAY, July 31, 2023 – Outcomes are encouraging for the first three living kidney donors with HIV, according to research published online July 24 in The Lancet Regional Health: Americas. In a...
Younger Kidney Cancer Patients on VEGF Inhibitors at Elevated Risk for Hypertension
WEDNESDAY, July 26, 2023 – Hypertension during treatment is common among adolescents and young adults (AYAs) being treated with vascular endothelial growth factor (VEGF) inhibitors for renal cancer,...
FDA Approves Soaanz (torsemide) for Edema Treatment in Patients with Heart Failure and Renal Disease
VIENNA, VA. (PRWEB) JUNE 21, 2021 Sarfez Pharmaceuticals announced today approval by the U.S. Food and Drug Administration (FDA) of the Virginia-based company’s New Drug Application for Soaanz, a o...
FDA Approves Jynarque (tolvaptan) to Slow Kidney Function Decline in Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease
April 24, 2018 – TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved Jynarque (tolvaptan) as the first drug...
FDA Approves Amgen's Parsabiv (etelcalcetide) for Secondary Hyperparathyroidism in Adult Patients on Hemodialysis
THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv (etelcalcetide) for the treatment of...
Ask a question
To post your own question to this support group, sign in or create an account.